Seeking Alpha's product team is responsible for the development of all of our product-related projects from start to finish. These projects include the Seeking Alpha Portfolio apps on the App Store and Google Play, our Real Time email alert product, and optimization across the Seeking Alpha website.
The purpose of this profile is to allow us to share with our readers all new product developments. Please follow us on Seeking Alpha to receive updates. We look forward to your input and feedback!
SA Product Team
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
I am an analyst and CFA Charterholder that gained experience in the investment industry through positions as a proprietary trader and a portfolio management administrator. I began contributing to Seeking Alpha as a way to share my thoughts on the biopharmaceutical industry. I discussed ways to minimize risk in biopharmaceutical investing through conservative pipeline valuation and balance sheet analysis to identify companies presenting a compelling valuation to potential investors. I also touched on ways to apply knowledge of the markets to improve personal finance. My pieces included either stock-specific analysis or general biopharmaceutical investing discussion through my Biotech Weekly blog. My research appeared on the websites of CNBC, Seeking Alpha, Reuters, Google Finance, Morningstar, NASDAQ, and MarketWatch.
Note: Articles and comments are my own opinions, are not related to the opinions of my employer, and should not be considered investment advice. Make sure to do your own due diligence before making an investment decision. Thanks!
Earned a Doctorate in Pharmacy (Pharm.D.) in 2010 and Pre-Pharmacy/B.S. in Molecular Biology in 2006. Over six years of direct experience in translational research in oncology investigating the molecular/cellular mechanisms of carcinogenesis focused on biomarker identification and validation working in a multi-disciplinary matrix environment across academia, contract research organizations and industry.
Analyst Tip Ranks: https://www.tipranks.com/experts/dr.-paul-nunzio-desantis%252C-pharm.d
To avoid criticism, do nothing, say nothing, be nothing. -Elbert Hubbard.
I have a Masters degree in Computer Science, and worked for 14 years in development, technical publications and software quality assurance. I have been investing for 20 years. Currently, I do writing, international editing, and photography. My short fiction can be found at http://50centflash.com/ "The fascination with the human face has never left me... Every face I see seems to hide - and sometimes fleetingly to reveal - the mystery of another human being. Capturing this revelation became my goal and passion." – Photographer Philippe Halsman
Curis, Inc. (CRIS) - NasdaqGM rated best investment going forward in Biotech for the remainder of 2014 and certainly for 2015.
Past Results - Achillion Pharmaceuticals, Inc. (ACHN) was issued a best investment rating on April 14, 2014 and it's hoped that on June 16, 2014 that investors locked in profit near the highs. The high that day was $8.05. The best investment rating was issued from the $2.70's area.
Athersys, Inc. (ATHX) - NasdaqCM In 2013 ATHX in the $1.60's area was issued a best investment notice. Followed up with several articles pointing out its potential. It's hoped investors took profit over $4 in early 2014. Today ATHX and its MultiStem is of high risk with one "no efficacy" phase II trial in 2014 reporting. For this reason ATHX is a buy only under $1.60 again today. This will limit downside to some degree if MultiStem fails again to show efficacy in a second phase II trial.
Other past calls were CLDX, ACUR and ALNY.
I am a semi-retired investor mainly trading equities & bonds. Most of my career was spent as an investment analyst in the front office of a private banking house In Geneva. Prior to that I worked for the Emerging Markets desk of a major banking house in London. Now that I'm retired, I write mainly about my lifelong interest, which is science and biology. I now live in Cyprus, on the periphery of the EU taking up the financial chaos from all sides.
I am the founder of the Braeburn Group of independent AAPL analysts and author of the Posts At Eventide web presence.
The objective of my work is to benefit readers seeking to understand Apple's financial performance and to provide a repository of information and analysis at my web presence for other independent AAPL analysts preparing quarterly estimates and share price forecasts.
In addition to following Apple, I maintain a keen interest in the personal technology product markets and follow publicly traded enterprises offering technology products and services to consumers.
Robert Paul Leitao
Intelligent Speculator is a market discussion and research group that focuses mainly on technology stocks and macroeconomic trades. Intelligent Speculator does provide new stock picks usually on a weekly basis that are either outright or long/short trades. Intelligent Speculator provides views of the different trends in the internet marketplace and its effects on the stocks involved. Since the author has both a financial (CFA exams completed) and a technology-based (through various experiences as webmaster/strategist) experience, he has an advantage in looking through the numbers. Visit Intelligent Speculator (http://www.intelligentspeculator.net/)
Colgate University, BA degree in Geology. Owner of Bristol Bay Flies (www.bristolbayflies.com).
Associate member, American Association of Petroleum Geologists. Interests in fly fishing, investing, coin collecting, backpacking, and organic gardening.
I am business graduate with a professional certification in F&A. I have been associated with the academic field, teaching both short and long courses on Finance and Accounting but my passion is following and writing about good investments.
Please note that I do not read comments posted here, nor respond to messages here. I don't have the time. If you want my attention, you must seek it directly at my blog.
David J. Merkel, CFA — From 2003-2007, I was a leading commentator at the excellent investment website RealMoney.com (http://www.RealMoney.com). Back in 2003, after several years of correspondence, James Cramer invited me to write for the site, and now I write for RealMoney on equity and bond portfolio management, macroeconomics, derivatives, quantitative strategies, insurance issues, corporate governance, etc. My specialty is looking at the interlinkages in the markets in order to understand individual markets better.
I no longer contribute to RealMoney because my work duties have gotten larger, and I began this blog to develop a distinct voice with a wider distribution.
In 2008, I became the Chief Economist and Director of Research of Finacorp Securities (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/02-08-2008/0004752449&EDATE=). Finacorp went into liquidation in June 2010, after which I decided to open my own asset management shop, Aleph Investments, LLC. I manage stock and bond portfolios for clients.
Until 2007, I was a senior investment analyst at Hovde Capital, responsible for analysis and valuation of investment opportunities for the FIP funds, particularly of companies in the insurance industry. I also managed the internal profit sharing and charitable endowment monies of the firm.
Prior to joining Hovde in 2003, I managed corporate bonds for Dwight Asset Management. In 1998, I joined the Mount Washington Investment Group as the Mortgage Bond and Asset Liability manager after working with Provident Mutual, AIG and Pacific Standard Life.
My background as a life actuary has given me a different perspective on investing. How do you earn money without taking undue risk? How do you convey ideas about investing while showing a proper level of uncertainty on the likelihood of success? How do the various markets fit together, telling us us a broader story than any single piece? These are the themes that I will deal with in this blog. I hold bachelor’s and master’s degrees from Johns Hopkins University.
In my spare time, I take care of our eight children with my wonderful wife Ruth. Visit this site: The Aleph Blog (http://alephblog.com/)
Over 20 years experience in investing, modeling, forecasting, and analytics. I concentrate my investment research on small to mid-cap medical device and biotech companies. My trading style is mostly catalyst-based (catalyst with likely success), generally holding stocks from days to weeks, relying on the catalyst as a potential backstop; a smaller allocation of funds goes to longer-term picks.
In previous years, I published a small-cap medical stock newsletter, which featured the the opinions of medical practitioners.
Uncovering select special situation stocks.
California Real Estate Broker
CEO and President of Gibralter Financial and Real Estate Services from 2001 to 2008.
CEO of All Valley Mortgage 1993-1995
Private investor, Author and trader from 1999 to present.
Value Digger holds MSc. in Electrical Engineering, speaks four languages and has lived in the U.S. for many years. He is a full-time, deep value investor and a well-known freelance writer who has been consistently ranked in the TOP-100 on TipRanks out of over 6,000 financial bloggers and analysts since 2012.
Specifically, he is a Seeking Alpha Author with one of the highest Followers per Article (F/A) rates. His F/A rate in Seeking Alpha exceeds 30 followers per article. Also, he is the Publisher and Editor of "The Alpha Discoverer", an insightful investment newsletter on The Maven (MVEN). Additionally, he is an Author for Stockhouse.com, Canada's #1 financial portal and one of North America's largest small cap investor communities with over 1 million unique visitors a month.
In 2014, Value Digger created a big community of deep value investors on his own website www.nathansbulletin.com. In 2015, Value Digger launched "Value Investor's Stock Club" on Seeking Alpha, a top-ranked deep value research service which includes an unparalleled, actively-managed and high-return Portfolio of unknown/underfollowed stocks. In 2017, Value Digger launched "The Alpha Discoverer", an insightful investment newsletter on TheMaven (MVEN) platform.
The Quarterly Performance Reviews PROVE his high returns and are available to his subscribers on Seeking Alpha and TheMaven. For reference, when Value Digger was managing money in the early 2000s, his Portfolio's annual ROI consistently exceeded 70%. His Premium Research is based on a comprehensive review of company-specific factors, macro conditions, competitors and the industry trends. Value Digger uses his analytical skills, goes against the grain and repeatedly discovers disconnects in a variety of sectors.
When it comes to his publicly-available picks and his free articles, Value Digger has a success rate of ~70%, an average return per recommendation of ~20% and a 5-star rating (TipRanks.com), which is the highest category quality ranking used to evaluate financial experts. TipRanks.com is a comprehensive investing tool that allows private investors and day traders to see the measured performance of anyone who publicly provides financial advice. TipRanks.com collects data, evaluates and ranks over 6,000 financial experts worldwide.
After 30 years of investing experience in the international markets (U.S., Canada, Australia, Europe), Value Digger has formulated a deep understanding of valuation analysis and his investment philosophy is firmly grounded in Ben Graham-style value-oriented opportunities that often have an assymetric risk/reward profile. On that front, he has created a unique proprietary database with thousands of publicly-traded companies per sector, which helps him spot the bargains and the bubbles before many investors find them.
"Prediction is very difficult, especially if it's about the future." Nils Bohr
Leading pharmaceutical companies invest billions of dollars each year in research and development with little or no guarantee of a return on their investment.
With the average cost of developing a new drug hitting the $800 million mark, accurately forecasting the market potential for new compounds is becoming an essential tool in long-term strategic planning.
Forecasting is also essential in understanding how the dynamics of a market are changing, evaluating licensing and acquisition opportunities for a particular therapeutic candidate, and raising the awareness of company executives of both current and potential future competitors.
Last, but not least, pharmaceutical product forecasting provides precious building blocks for modeling and simulation exercises that investment analysts need to conduct on a continuous bases to estimate return-on-investment decisions and fine tune their portfolios.
Pharma Reports specializes in modeling and publishing short and medium term event-impacted linear forecasts for both new and established drugs.
Since actual brand performance depends on how the marketing company allocates its resources and how the competition responds to changes in market shares, we revise our forecasts periodically as new data points become available.
Dr. Kris has two degrees from MIT because one just wasn't enough. Her life goal was to figure out the universe and having done that (at least to her satisfaction), she decided to tackle something even more difficult—the stock market.
Applying the scientific method along with an insatiably curious mind, she began trading stocks, futures, and options in order to find the holy grail to market success. She's discovered to her immense satisfaction that not only is there one way to succeed but many. Combining her love of cooking with the stock market, she's devised recipes for investment success designed to please the palate of most investors. Dr. Kris currently manages a private equity long/short portfolio and writes of her current research projects that appear on her website, StockMarketCookBook.com.
Her most exciting project is applying market timing models to Modern Portfolio Theory to not only give greater returns but at substantially lower levels of risk. (See PortfolioPreserver.com for further information.)
Peter Geschek is a freelance writer, investor and the publisher of www.medfrontiers.com website. This is a site for medical innovation news and clinical trials news. Short, concise, important information about the latest is biotech and pharmaceuticals.
I am an individual investor who has been actively involved in the healthcare and biotechnology space for over 15 years. I hold a PhD in the biomedical sciences and have worked in both large pharmaceutical and small biotech companies. I make investments based on the fundamentals of a company and if I believe they have a superior technology or products compared to the competition. I'm an investor who believes patience pays off.
As an avid stock trader I am always searching for new opportunities. I utilize a very research heavy approach in my strategy that has done quite well for me over the years. I have earned a degree in Physics and an MBA in Finance. Although my educational background is an unconventional pairing, both have served me well. I am currently a consultant that specializes in small business development.
I currently work in the health care field. I am a long-term investor who conducts extensive research as part of my due diligence when considering a stock. My articles hope to provide unbiased background information to help others make an educated decision.
Although I recommend a diversified portfolio, I have a special interest in biomedical firms. Since biomedical investing is often very risky, I believe that research is especially important when investing in this industry. I find biomedical investing rewarding because these investments may not only yield high returns but also help save lives.
Theodore J. Cohen, Ph.D., a research scientist, has been an investor for more than 50 years. Since 1980, he has focused his attention on investment research and investigative analyses of companies developing therapeutic drugs in the biotech sector. Dr. Cohen is a frequent contributor of Guest Opinions (op-ed pieces) to the Bucks County (PA) Courier Times (circulation: 80,000), where, since 2007, he has addressed such varied subjects as the conflicts of interest (COIs) associated with two members of the Provenge advisory committee (AC); the U.S. Senate’s Durbin Amendment, to tighten COI reviews of FDA AC members; and naked short selling. Cohen is the author of the award-winning novels Death by Wall Street: Rampage of the Bulls (AuthorHouse, 2010) and House of Cards: Dead Men Tell No Tales (Outskirts Press, 2011), which were inspired by real events. The books are available from Amazon.com, B&N, and 26,000 online bookstores worldwide. For details, see http://www.theodore-cohen-novels.com.
James Gruber is a 15-year veteran of Asian financial markets. Through this time, James has covered Asia as a leading Fund Manager, stockbroking analyst and journalist. Most recently, he spent two years as a Portfolio Manager for Asian Equities at AMP Capital, which manages Asian and China A-share funds totalling US$1bn. The performance of the China A-share fund was ranked no. 1 globally over one and two years during this time there.
For five years prior to this, James was a Research Analyst at Asian brokerage, CLSA, where he covered multiple sectors in Hong Kong, Singapore, Australia, Malaysia and Indonesia. He was the no. 1 Asiamoney ranked analyst for the materials sector in Indonesia in 2007. He was also ranked by Asiamoney as the 13th best overall analyst in Australia in 2009.
And in a former life, James was a television and radio news journalist at the Australian Broadcasting Corporation. He founded Asia Confidential in July 2012.
James is a highly sought-after contributor to financial publications including Forbes, Zero Hedge and Financial Sense as well as a regular guest on CNBC.
He is also an occasional contributor to the highly regarded institutional research firm, Forensic Asia.
Semiconductor Veteran of over 20 years working at Intel and several prominent startups like Cyrix and Transmeta. I was a co-founder in an FPGA startup for nearly 5 years and now work with a leading edge non-volatile memory startup building Resistive RAM memories, which will eventually take the place of Flash as a lower power, higher performance and more economical solution.
I write occasionally on the mobile markets and the semiconductors that power them. Transmeta was the company that first highlighted the need for all day computing in the PC market. I was proud to be a part of the launch of the first truly low power x86 processor, which Intel then had to address.
25-year military officer, Annapolis, Naval aviator, EA-6B Prowler pilot. Electronic warfare expert. Operational test director and pilot for weapons and avionics. Squadron and air base commander. 7 times deployed to Middle East and Southwest Asia. 22 months on the ground in Iraq. 3 years as Pentagon strategic planner on Joint Staff. 3 years as faculty instructor of strategy and warfighting at the Air War College. Degrees in physics, strategy, and history. Published papers on energy security and biofuels.
I am an experienced individual investor who has been trading merger arbitrage stocks and options since the 90's. I am a writer with a Master of Science from Northwestern University and I truly enjoy writing articles about the stock market. I try to look for opportunities where the odds are in my favor and there is a definite edge. On Seeking Alpha my articles will aim to provide insight and favorable risk/reward for the readers.However, I am not an investment advisor so any recomendations or ideas I write about in my articles, blogs, or comments shouldn't be taken as investment advice. I recommend using my writings as a starting point to which you should add your own research or that of an investment advisor.
"Any time you make a bet with the best of it, where the odds are in your favor, you have earned something on that bet, whether you actually win or lose the bet. By the same token, when you make a bet with the worst of it, where the odds are not in your favor, you have lost something, whether you actually win or lose the bet."
-David Sklansky, "The Theory of Poker"